SE9804314D0 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
SE9804314D0
SE9804314D0 SE9804314A SE9804314A SE9804314D0 SE 9804314 D0 SE9804314 D0 SE 9804314D0 SE 9804314 A SE9804314 A SE 9804314A SE 9804314 A SE9804314 A SE 9804314A SE 9804314 D0 SE9804314 D0 SE 9804314D0
Authority
SE
Sweden
Prior art keywords
dosage forms
blocking agent
calcium channel
channel blocking
pharmaceutical formulation
Prior art date
Application number
SE9804314A
Other languages
Swedish (sv)
Inventor
Arne Eek
Lars Josefsson
Per Johan Lundberg
Aake Pilbrant
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9804314A priority Critical patent/SE9804314D0/en
Publication of SE9804314D0 publication Critical patent/SE9804314D0/en
Priority to BR9916224-5A priority patent/BR9916224A/en
Priority to CA002352613A priority patent/CA2352613A1/en
Priority to CN99816118A priority patent/CN1334731A/en
Priority to NZ511999A priority patent/NZ511999A/en
Priority to JP2000587768A priority patent/JP2002532425A/en
Priority to KR1020017007344A priority patent/KR20010093822A/en
Priority to PCT/SE1999/002315 priority patent/WO2000035448A1/en
Priority to AU20186/00A priority patent/AU776079B2/en
Priority to IL14338699A priority patent/IL143386A0/en
Priority to EP99963820A priority patent/EP1150677A1/en
Priority to ZA200104273A priority patent/ZA200104273B/en
Priority to NO20012915A priority patent/NO20012915L/en
Priority to HK02103023.3A priority patent/HK1041224A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

This invention is related to new oral pharmaceutical dosage forms comprising a proton pump inhibitor, i.e. a H<+>, K<+> -ATPase inhibitor, a gastric antisecretory prostaglandin analogue compound, and optionally an additional drug such as a calcium channel blocking agent, especially for use in the treatment and prophylaxis of gastrointestinal disorders. More specifically the invention is related to new dosage forms comprising omeprazole and misoprostol. The invention is also related to a combination of the three categories of drugs, i.e. the H<+>, K<+> -ATPase inhibitor, the gastric antisecretory prostaglandin analogue, and the calcium channel blocking agent. Furthermore, the invention refers to a method for the manufacture of the described dosage forms and their use in medicine, as well as blister packs comprising these medicaments.
SE9804314A 1998-12-14 1998-12-14 New pharmaceutical formulation SE9804314D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE9804314A SE9804314D0 (en) 1998-12-14 1998-12-14 New pharmaceutical formulation
EP99963820A EP1150677A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
KR1020017007344A KR20010093822A (en) 1998-12-14 1999-12-10 New Pharmaceutical Formulation
CA002352613A CA2352613A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
CN99816118A CN1334731A (en) 1998-12-14 1999-12-10 Pharmaceutical formulation
NZ511999A NZ511999A (en) 1998-12-14 1999-12-10 Pharmaceutical formulation comprising a H+,K+-ATPase inhibitor and a gastric antisecretory prostaglandin analogue
JP2000587768A JP2002532425A (en) 1998-12-14 1999-12-10 New pharmaceutical formulations
BR9916224-5A BR9916224A (en) 1998-12-14 1999-12-10 Oral pharmaceutical dosage form, processes for the manufacture of a fixed dosage form, for the treatment and prophylaxis of gastrointestinal disorders and to prevent gastrointestinal side effects, use of a dosage form, combination, and ampoule packaging
PCT/SE1999/002315 WO2000035448A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
AU20186/00A AU776079B2 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
IL14338699A IL143386A0 (en) 1998-12-14 1999-12-10 Pharmaceutical dosage form comprising a h+, k+ -atpase inhibitor and gastric antisecretory prostaglandin analogue compound
ZA200104273A ZA200104273B (en) 1998-12-14 2001-05-24 New pharmaceutical formulation.
NO20012915A NO20012915L (en) 1998-12-14 2001-06-13 New pharmaceutical formulation
HK02103023.3A HK1041224A1 (en) 1998-12-14 2002-04-22 New pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804314A SE9804314D0 (en) 1998-12-14 1998-12-14 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE9804314D0 true SE9804314D0 (en) 1998-12-14

Family

ID=20413648

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804314A SE9804314D0 (en) 1998-12-14 1998-12-14 New pharmaceutical formulation

Country Status (14)

Country Link
EP (1) EP1150677A1 (en)
JP (1) JP2002532425A (en)
KR (1) KR20010093822A (en)
CN (1) CN1334731A (en)
AU (1) AU776079B2 (en)
BR (1) BR9916224A (en)
CA (1) CA2352613A1 (en)
HK (1) HK1041224A1 (en)
IL (1) IL143386A0 (en)
NO (1) NO20012915L (en)
NZ (1) NZ511999A (en)
SE (1) SE9804314D0 (en)
WO (1) WO2000035448A1 (en)
ZA (1) ZA200104273B (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US8268333B2 (en) 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
ITMI20020515A1 (en) * 2002-03-12 2003-09-12 Jagotec Ag SYSTEM FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE INGREDIENTS
WO2004082665A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
TW200510002A (en) * 2003-06-06 2005-03-16 Takeda Chemical Industries Ltd Solid pharmaceutical preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2005289867A (en) * 2004-03-31 2005-10-20 Lintec Corp Agent for peroral administration
CN1311824C (en) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 Enteric coated micro particle preparation of omeprazole and its preparation method
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
PL1871380T3 (en) 2005-04-12 2012-03-30 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
EP1987820A1 (en) * 2007-05-04 2008-11-05 Christian Fiala, Ph. D. Slow release misoprostol for obstetric and/or gynaecological applications
CN102078615A (en) * 2011-01-21 2011-06-01 北京华禧联合科技发展有限公司 Composition of proton pump inhibitor and gastric mucosa protective agent
EP3169314A1 (en) * 2014-07-17 2017-05-24 Dow Global Technologies LLC Ethylcellulose dispersion and film
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN110621314A (en) 2017-01-04 2019-12-27 艾克萨姆治疗公司 Pharmaceutical composition comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam

Also Published As

Publication number Publication date
AU776079B2 (en) 2004-08-26
AU2018600A (en) 2000-07-03
CN1334731A (en) 2002-02-06
HK1041224A1 (en) 2002-07-05
KR20010093822A (en) 2001-10-29
NZ511999A (en) 2002-10-25
BR9916224A (en) 2001-09-04
WO2000035448A1 (en) 2000-06-22
IL143386A0 (en) 2002-11-10
CA2352613A1 (en) 2000-06-22
ZA200104273B (en) 2002-08-26
NO20012915D0 (en) 2001-06-13
JP2002532425A (en) 2002-10-02
NO20012915L (en) 2001-08-13
EP1150677A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
SE9804314D0 (en) New pharmaceutical formulation
BR9506029A (en) Oral pharmaceutical form of multiple unit dosage in tablet process for the preparation of it for inhibiting the secretion of gastric acid in mammals and in man for the treatment of inflammatory gastrointestinal diseases in manifers and in man and packaging of a transverse pressure ampoule
UA88523C2 (en) Dosage form of roflumilast for topical administration
ATE359077T1 (en) ORAL ADMINISTRATION OF 6-HYDROXY-OXYMORPHONE AS ANALGESIC
ATE477804T1 (en) METHOD FOR TREATING INFLAMMATORY DISEASES OF THE DIGESTIVE TRACT USING TOPICAL CORTICOSTEROIDS
SE0100568D0 (en) Compounds
HK1076605A1 (en) Formulations
BR9814378A (en) Enteric coated pharmaceutical prolonged release dosage form of a h +, k + -atpase inhibitor, processes for manufacturing it, to improve inhibition of gastric acid secretion, to improve the therapeutic effect in the treatment of gastrointentinal disorders, to receive a prolonged plasma profile of an h +, k + -atpase inhibitor, and, uses of a pharmaceutical composition and h +, k + -atpase inhibitor
DE50203456D1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
SE9901573D0 (en) New compounds
RU2007104774A (en) COMBINATION OF ANTI-HIV REVERSE TRANSCRIPTASE AND PROTEASES INHIBITORS
HUP0402577A2 (en) Indole derivatives as inhibitors of cytosolic phospholipase a2, process for producing them and pharmaceutical compositions containing them
ECSP034826A (en) METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION OF LOW DOSE
HUP0302068A2 (en) Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
RU2003125274A (en) APPLICATION OF FLUMAZENIL IN THE PRODUCTION OF MEDICINE FOR TREATMENT OF ALCOHOL DEPENDENCE
NO20005912L (en) Sulfonyl acid or sulfonylamino-N- (heteroaralkyl) - azaheterocyclylamide compounds
YU84503A (en) Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
SE0100566D0 (en) Compounds
EA200401097A1 (en) MEDICAL FORM WITH ADJUSTABLE LIBERATION OF THE ACTIVE INGREDIENT
HK1079421A1 (en) Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
MXPA04005902A (en) Compressed oral pharmaceutical dosage form, with an enteric coating, which contains an acid-labile benzimidazole compound.
SE9901572D0 (en) New compounds
SE0201837D0 (en) Chemical compounds
SE0101692D0 (en) Compounds
BG108144A (en) New use